Bioconjugation Reagents and Services
Vector Laboratories provides expert-guided, collaborative linker development processes for bioconjugate therapeutic development.
Receive your quote directly from the manufacturer.
The success of functional molecular conjugates requires expert knowledge of both chemical biology and linker architecture. Collaborating with Vector Laboratories and leveraging our BioDesign process gives you access to critical bioconjugation expertise and unique linker IP. These critical elements help to maximize your development versatility, overcome resource constraints, enable you to manufacture at scale, and decrease your time-to-market.
Brochures
12 tools of click chemistry
In this product brochure, Vector Laboratories showcases its comprehensive portfolio of Click Chemistry tools, providing researchers with reliable, high-quality solutions designed to streamline workflows and deliver consistent, reproducible results across a wide range of applications.
Advantages of dPEG in ADC linker design
In this product brochure, Vector Laboratories presents case studies showcasing the benefits of incorporating dPEG into the linker-payload design as an overall strategy to improve efficacy, reduce accelerated clearance, and minimize toxicity. Vector Laboratories offers a range of dPEG linkers and modifiers for ADC development with an array of reactive groups, linker architectures, end capping, ethylene oxide lengths, and cleavable formats.
Click chemistry toolbox
In this product brochure, Vector Laboratories showcases its versatile collection of reagents, probes, and assay kits for biorthogonal labeling, imaging, enrichment, and proteomics.
Bispecific ADCs targeting the cancer, not the patient
Tuesday, July 28 at 15:00 BST | 16:00 CEST | 10:00 EDT | 07:00 PDT
Bispecific antibody-drug conjugates (ADCs) represent an emerging frontier in targeted cancer therapy, combining the precision of antibody-based targeting with the potency of cytotoxic payloads. By recognizing two distinct tumor-associated markers rather than one, bispecific ADCs can improve tumor selectivity, helping to distinguish cancer cells from healthy tissue and potentially reducing off-target effects. As the field advances, researchers are exploring innovative approaches to address longstanding challenges in efficacy, safety, and patient outcomes, making bispecific ADCs a rapidly growing area of interest in oncology research and drug development.
This SelectScience webinar introduces BiVictriX Therapeutics and its role as an early pioneer in bispecific, logic gated, ADCs. It will cover how ADCs are reshaping targeted cancer therapy and why bispecific targeting offers a route to improved tumor selectivity and reduced off-tumor toxicity. The presentation will also explore the key steps to take when designing a bispecific ADC, including target selection, antibody format, linker strategy, and payload choice, and how these decisions influence efficacy, safety, and clinical potential.
Advances in bioconjugation for next-generation therapeutics
Discover how advances in bioconjugation are transforming the design and optimization of next-generation therapeutics. In this SelectScience interview, Matthew Giese, Bioconjugate Field Application Scientist at Vector Laboratories, discusses the latest innovations shaping the field and explains how they are enabling greater precision and control over conjugate structure and function. Through customer examples spanning cancer vaccines, siRNA delivery, radiopharmaceuticals, cell therapy workflows, and multiplexed immunofluorescence, Matthew highlights the value of end-to-end bioconjugation solutions in streamlining development and optimization.
This video was filmed at AACR Annual Meeting 2026.
